Stocklytics Platform
Asset logo for symbol NVAX
Novavax
NVAX55
$11.63arrow_drop_down2.67%-$0.32
Asset logo for symbol NVAX
NVAX55

$11.63

arrow_drop_down2.67%

Performance History

Chart placeholder
Key Stats
Open$11.91
Prev. Close$11.95
EPS-2.62
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range11.43
12.12
52 Week Range3.53
23.86
Ratios
EPS-2.62

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Novavax (NVAX)

Novavax Inc (NVAX) is a biotechnology company that specializes in the development of vaccines for various infectious diseases. The company is focused on creating innovative vaccine candidates using its proprietary recombinant nanoparticle technology. NVAX stock has a volatile price history, with fluctuations driven by news events and market sentiment. Investors should be aware of the risks associated with investing in biotech stocks, as they can be highly speculative and subject to regulatory uncertainties.
As of the latest quote, NVAX stock is trading at $X per share, representing a market capitalization of $X billion. The stock has recently experienced a surge in trading volume, reflecting increased investor interest in the company. Novavax Inc has been in the news recently for its COVID-19 vaccine candidate, which has shown promising results in clinical trials. The company has received funding from various sources, including government grants and partnerships with other pharmaceutical companies.
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. John Charles Jacobs M.B.A.
Headquarters
Gaithersburg
Employees
1992
Exchange
NASDAQ
add Novavax  to watchlist

Keep an eye on Novavax

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Novavax 's (NVAX) price per share?

The current price per share for Novavax (NVAX) is $11.63. The stock has seen a price change of -$0.32 recently, indicating a -2.68% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Novavax (NVAX)?

For Novavax (NVAX), the 52-week high is $23.86, which is 105.16% from the current price. The 52-week low is $3.53, the current price is 229.46% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Novavax (NVAX) a growth stock?

Novavax (NVAX) has shown an average price growth of 0.41% over the past three years. It has received a score of -1 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Novavax as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Novavax (NVAX) stock price performance year to date (YTD)?

As of the latest data, Novavax (NVAX) has a year-to-date price change of 131.21%. Over the past month, the stock has experienced a price change of 0.87%. Over the last three months, the change has been -40.53%. Over the past six months, the figure is 107.31%. Looking at a longer horizon, the five-year price change stands at 111.45%.
help

Is Novavax (NVAX) a profitable company?

Novavax (NVAX) has a net income of -$545.06M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 71.59% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 39.01% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $983.7M, although specific revenue growth data is currently not available. The gross profit is $704.24M. Operating income is noted at -$415.03M. Furthermore, the EBITDA is -$240.84M.
help

What is the market capitalization of Novavax (NVAX)?

Novavax (NVAX) has a market capitalization of $1.91B. The average daily trading volume is 5.31M, indicating the stock's liquidity and investor engagement.

News

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media